IRIS
MORABITO, FORTUNATO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.888
AS - Asia 2.657
EU - Europa 1.191
SA - Sud America 760
Continente sconosciuto - Info sul continente non disponibili 127
AF - Africa 115
OC - Oceania 7
Totale 7.745
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.646
SG - Singapore 912
IT - Italia 668
BR - Brasile 550
CN - Cina 533
VN - Vietnam 446
HK - Hong Kong 214
BD - Bangladesh 172
DE - Germania 107
FR - Francia 101
AR - Argentina 70
CA - Canada 68
KR - Corea 61
GB - Regno Unito 58
FI - Finlandia 56
IN - India 53
MX - Messico 48
RU - Federazione Russa 41
IQ - Iraq 40
ZA - Sudafrica 34
EC - Ecuador 31
CO - Colombia 30
ID - Indonesia 30
NL - Olanda 28
PK - Pakistan 25
UA - Ucraina 24
VE - Venezuela 23
AT - Austria 22
TR - Turchia 22
NI - Nicaragua 20
UZ - Uzbekistan 19
CR - Costa Rica 17
GT - Guatemala 16
CL - Cile 15
JP - Giappone 15
PY - Paraguay 15
JM - Giamaica 14
PL - Polonia 13
SA - Arabia Saudita 13
TT - Trinidad e Tobago 13
HN - Honduras 12
MY - Malesia 12
PH - Filippine 12
KE - Kenya 11
MA - Marocco 11
PE - Perù 11
DZ - Algeria 10
EG - Egitto 10
ES - Italia 10
NP - Nepal 10
ET - Etiopia 9
TN - Tunisia 9
AE - Emirati Arabi Uniti 8
CW - ???statistics.table.value.countryCode.CW??? 8
SV - El Salvador 8
IL - Israele 7
JO - Giordania 7
UY - Uruguay 7
BG - Bulgaria 6
BO - Bolivia 6
CZ - Repubblica Ceca 6
KG - Kirghizistan 6
PA - Panama 6
PR - Porto Rico 6
RO - Romania 6
DO - Repubblica Dominicana 5
OM - Oman 5
SE - Svezia 5
SN - Senegal 5
AL - Albania 4
AU - Australia 4
AZ - Azerbaigian 4
BA - Bosnia-Erzegovina 4
CH - Svizzera 4
EE - Estonia 4
GP - Guadalupe 4
KZ - Kazakistan 4
SC - Seychelles 4
AM - Armenia 3
BE - Belgio 3
LB - Libano 3
LT - Lituania 3
LY - Libia 3
PS - Palestinian Territory 3
RS - Serbia 3
TH - Thailandia 3
TW - Taiwan 3
BB - Barbados 2
BN - Brunei Darussalam 2
DK - Danimarca 2
GA - Gabon 2
GY - Guiana 2
IE - Irlanda 2
NG - Nigeria 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
QA - Qatar 2
BH - Bahrain 1
BS - Bahamas 1
BW - Botswana 1
Totale 7.603
Salva come PNG Salva come JPEG
Città #
Singapore 375
San Jose 366
Council Bluffs 357
Ashburn 356
Dallas 235
Hong Kong 211
Ho Chi Minh City 152
Florence 147
Boardman 122
Beijing 107
Hefei 99
Hanoi 95
Milan 93
New York 65
Seoul 60
São Paulo 60
Lauterbourg 58
Los Angeles 57
Santa Clara 49
Munich 47
Chicago 42
The Dalles 42
Helsinki 39
Shanghai 39
Phoenix 37
Rome 35
Atlanta 30
Longmont 29
North Bergen 28
Da Nang 25
Haiphong 23
Noto 22
Rio de Janeiro 22
Sesto Fiorentino 22
Washington 22
Managua 19
Montreal 19
Miano 18
Naples 18
Baghdad 17
Quito 17
Guangzhou 16
Tashkent 16
Brooklyn 15
Mexico City 15
Guatemala City 14
Bari 13
Brasília 12
Denver 12
Orem 12
San José 12
Tokyo 12
Turin 12
Vienna 12
Biên Hòa 11
Johannesburg 11
Nairobi 11
Ogden 11
Omaha 11
Amsterdam 10
Brescia 10
Caracas 10
Guayaquil 10
Irvine 10
Nuremberg 10
Turku 10
Addis Ababa 9
Belo Horizonte 9
Buffalo 9
Frankfurt am Main 9
Kingston 9
Mumbai 9
Ribeirão Preto 9
Warsaw 9
Wuhan 9
Bologna 8
Boston 8
Chennai 8
Fortaleza 8
Genoa 8
Karachi 8
London 8
Medellín 8
Ninh Bình 8
Palermo 8
Portland 8
San Francisco 8
Seattle 8
Thái Nguyên 8
Amman 7
Campinas 7
Can Tho 7
Charlotte 7
Dhaka 7
Hillsboro 7
Kuala Lumpur 7
Lahore 7
Naaldwijk 7
Padua 7
Paris 7
Totale 4.244
Salva come PNG Salva come JPEG
Nome #
Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? 200
Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients 193
Vaccination in Multiple Myeloma: Challenges and Strategies 156
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 155
Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives 146
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy 144
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 143
Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma 139
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 139
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 138
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? 138
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 136
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 134
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 129
The role of corticosteroids in the current treatment paradigm for myelofibrosis 129
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells 128
TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions 127
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 126
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 126
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study 125
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 120
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair? 119
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 116
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 116
Iron chelation therapy 111
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 108
Belantamab mafodotin in multiple myeloma 108
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study 103
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 103
Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: Findings from a prospective single-center cohort study 102
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells 102
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 102
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study 102
Acalabrutinib in chronic lymphocytic leukemia 102
Myelodysplastic syndromes with ring sideroblasts 101
Selinexor in multiple myeloma 101
Comparative Analysis of Bispecific Antibodies and CAR T‐Cell Therapy in Follicular Lymphoma 101
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 101
Advances and Challenges in Quizartinib‐Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies 98
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature 97
Elotuzumab in multiple myeloma 94
Avatrombopag for the Treatment of Immune Thrombocytopenia 93
Maintenance therapy after ASCT in newly diagnosed multiple myeloma patients: single agent versus combination drugs 93
Ivosidenib in acute myeloid leukemia 92
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 92
Rilzabrutinib for the Treatment of Immune Thrombocytopenia 90
Glasdegib for the treatment of acute myeloid leukemia 86
Therapy‐Related Acute Promyelocytic Leukemia: Case Series and Current Insights 84
Early progression beyond first‐line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study 83
Zanubrutinib for the treatment of chronic lymphocytic leukemia 82
Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity 80
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies 79
REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA 79
Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura 77
Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions 75
Treatment-Free Remission in Chronic Myeloid Leukemia: Revisiting the "W" Questions 75
TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia 73
Mosunetuzumab for the treatment of follicular lymphoma 71
Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents 65
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens 65
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study 60
Venetoclax in acute myeloid leukemia 59
Isatuximab in multiple myeloma 58
The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia 56
Real‐World Evaluation of Oral Decitabine/Cedazuridine in Elderly Patients With Acute Myeloid Leukemia 48
Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy 46
Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort 45
Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies 39
Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs 37
Reshaping multiple myeloma treatment: recent breakthroughs 37
Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy 37
Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials 36
Targeting the Menin– KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation 35
Relapse Despite MRD Negativity in Multiple Myeloma: Toward Integrated Risk Prediction 34
Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives 32
Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM 30
Therapeutic Strategies for Relapsed or Refractory B‐Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies 28
Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies 27
Immunogenetic Architecture of Chronic Lymphocytic Leukemia at Early Stage: Insights from the O-CLL1 Cohort 26
Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration 26
Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions 25
Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies 24
First‐Line Treatment of IGHV ‐Unmutated Chronic Lymphocytic Leukemia: A Network Meta‐Analysis of Targeted and Chemoimmunotherapy Regimens 23
From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management 21
The Gut Microbiota in Hematologic Malignancies: Mechanisms, Clinical Associations, and Translational Opportunities 21
Gut Microbiota and Acute Myeloid Leukemia: State of the Art, Clinical Signals, and Translational Opportunities 20
What Does It Really Mean to Say That a Patient With a Hematologic Malignancy Is “Cured”? 19
High-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohort 19
Regional Standardization of CLL Management: Results of a Delphi Consensus Process 19
From static risk to dynamic disease monitoring: the role of MRD and immune profiling in multiple myeloma 18
Bispecific Antibodies for Acute Myeloid Leukemia: From Bone Marrow Immune Niche to Clinical Translation 17
To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy 16
Intraclonal Enrichment of IL-23 Receptor Complex Expression in the Proliferative Fraction of Chronic Lymphocytic Leukemia 15
Rethinking On‐Target Off‐Tumor Toxicity as a Hematopoietic Continuum 14
Unexplained Anemia of Aging: From Residual Label to Mechanism‐Based Syndrome 14
Minimal residual disease in diffuse large B‐cell lymphoma after first‐line therapy: Defining the continuum from metabolic remission to molecular clearance 14
Mechanisms of post-transplant AML relapse and therapeutic implications 11
When MRD Is Not MRD: A Context-Dependent Interpretation in Clinical Decision-Making: A Context‐Dependent Interpretation in Clinical Decision‐Making 11
Multiple Myeloma and the Illusion of the Evidence Pyramid 11
Bridging Randomized Trial Efficacy and Real‐World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real‐World Evidence for Individualized Care 9
Totale 7.729
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.410
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.410
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202368 0 0 0 0 0 0 30 3 4 4 21 6
2023/2024523 9 14 116 86 50 84 27 13 15 6 14 89
2024/20251.227 43 89 32 66 59 53 30 58 177 130 123 367
2025/20264.257 442 238 387 287 626 291 464 195 358 411 292 266
2026/20271.670 319 191 396 764 0 0 0 0 0 0 0 0
Totale 7.745